Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 5/20 | 0.57 |
| ▸ | UMPS | P11172 | 1/20 | 0.55 |
| ▸ | P2RY2 | P41231 | 9/20 | 0.52 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.50 |
| ▸ | DNPH1 | O43598 | 3/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.47 |
| ▸ | FBP1 | P09467 | 1/20 | 0.46 |
| ▸ | ATIC | P31939 | 1/20 | 0.46 |
| ▸ | NT5E | P21589 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19998417 | 1.00 | P2RY6 (0.57) | P2RY6UMPSP2RY2P2RY4DNPH1 | |
| SCHEMBL19308914 | 0.93 | P2RY6 (0.68) | P2RY6P2RY2P2RY4NT5E | |
| SCHEMBL19308864 | 0.93 | P2RY6 (0.68) | P2RY6P2RY2P2RY4NT5E | |
| SCHEMBL15279683 | 0.93 | P2RY6 (0.68) | P2RY6P2RY2P2RY4NT5E | |
| SCHEMBL15276436 | 0.93 | P2RY6 (0.68) | P2RY6P2RY2P2RY4NT5E | |
| SCHEMBL15276353 | 0.93 | P2RY6 (0.68) | P2RY6P2RY2P2RY4NT5E | |
| SCHEMBL15279706 | 0.93 | P2RY6 (0.68) | P2RY6P2RY2P2RY4NT5E | |
| SCHEMBL21450093 | 0.93 | P2RY6 (0.68) | P2RY6P2RY2P2RY4NT5E | |
| SCHEMBL19998460 | 0.91 | P2RY6 (0.66) | P2RY6P2RY2P2RY4 | |
| SCHEMBL20003870 | 0.91 | P2RY6 (0.66) | P2RY6P2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180085386-A1 | URIDINE MONOPHOSPHATE AND TRIPHOSPHATE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | TUFTS UNIVERSITY | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180085386-A1 | URIDINE MONOPHOSPHATE AND TRIPHOSPHATE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | P2RY6, UPP1, UMPS | P2RY6 1/4885UMPS 3/4885P2RY2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.